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A B S T R A C T
Objectives: To evaluate the eﬀect of an intervention to optimize TB/HIV integration on patient outcomes.
Methods: Cluster randomised control trial at 18 primary care clinics in South Africa. The intervention was
placement of a nurse (TB/HIV integration oﬃcer) to facilitate provision of integrated TB/HIV services, and a lay
health worker (TB screening oﬃcer) to facilitate TB screening for 24months. Primary outcomes were i) in-
cidence of hospitalisation/death among individuals newly diagnosed with HIV, ii) incidence of hospitalisation/
death among individuals newly diagnosed with TB and iii) proportion of HIV-positive individuals newly diag-
nosed with TB who were retained in HIV care 12months after enrolment.
Results: Of 3328 individuals enrolled, 3024 were in the HIV cohort, 731 in TB cohort and 427 in TB-HIV cohort.
For the HIV cohort, the hospitalisation/death rate was 12.5 per 100 person-years (py) (182/1459py) in the
intervention arm vs. 10.4/100py (147/1408 py) in the control arms respectively (Relative Risk (RR) 1.17 [95%
CI 0.92–1.49]).For the TB cohort, hospitalisation/ death rate was 17.1/100 py (67/ 392py) vs. 11.1 /100py (32/
289py) in intervention and control arms respectively (RR 1.37 [95% CI 0.78–2.43]). For the TB-HIV cohort,
retention in care at 12months was 63.0% (213/338) and 55.9% (143/256) in intervention and control arms (RR
1.11 [95% 0.89–1.38]).
Conclusions: The intervention as implemented failed to improve patient outcomes beyond levels at control
clinics. Eﬀective strategies are needed to achieve better TB/HIV service integration and improve TB and HIV
outcomes in primary care clinics.
Trial registration: South African Register of Clinical Trials (registration number DOH-27-1011-3846).
1. Introduction
South Africa faces a large burden of the dual epidemics of tu-
berculosis (TB) and HIV. With an HIV prevalence of 12.8% in the
general population [1], an estimated TB incidence rate of 781 per
100,000 of the population [2], and HIV positivity of 59% among in-
dividuals diagnosed TB in 2016 [2], the country could beneﬁt from
improved integration of TB and HIV services. The integration of TB and
HIV services refers to co-location and joint delivery of TB and HIV-
related services. TB and HIV integration comprise activities to reduce
morbidity and mortality from HIV among individuals with TB - HIV
counselling and testing, initiation of cotrimoxazole preventive therapy
(CPT) and earlier initiation of antiretroviral therapy (ART) as well ac-
tivities to reduce morbidity and mortality from TB among individuals
living with HIV - intensiﬁed case ﬁnding, isoniazid preventive therapy
(IPT), TB infection control and the early initiation of ART [3, 4]
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Diﬀerent models have been used to deliver integrated TB/HIV ser-
vices at primary care level [5, 6]. These models range from separate
services with referral between them to complete integration where care
for both diseases is provided by the same provider in the same con-
sultation [6]. Evidence of the beneﬁts of TB/HIV integration is limited
to evidence of improved TB treatment outcomes, increased ART uptake
and shorter time to ART initiation among HIV positive individuals
treated for TB [7–10]. Information on the eﬀectiveness of interventions
to improve integration of TB and HIV services and the eﬀect of such
integration on distal outcomes such as mortality, hospitalisations and
retention in care is however limited [6, 11–13]. We report on the
outcomes of a cluster randomised trial to evaluate the eﬀect of an in-
tervention to optimise integration of TB and HIV-related services on
morbidity (hospitalizations), mortality and retention in care among
individuals newly diagnosed with TB and individuals newly diagnosed
with HIV at primary care clinics in South Africa.
2. Methods
2.1. Study design and setting
The setting and methods of this cluster-randomised trial have been
previously reported. [14] Clusters comprised primary care clinics in a
sub-district of Ekurhuleni District, Gauteng province, South Africa. At
randomization in August 2011, all the participating clinics provided TB
and HIV services under the same roof, but these services were run se-
parately with varying levels of cross-referral between them – that is
they had co-location of services. This level of integration- co-location of
services- was assumed sub-optimal with the one-stop-shop model- a
model in which both TB and HIV services are provided by the same
provider in the same consultation- considered ideal. [15] In addition, in
the sub-district where the trial was implemented, there was an on-going
TB/HIV health systems strengthening programme whose main activities
were mentoring clinic nurses on ART and training on recording and
reporting for TB and HIV. At the time of clinic randomization, South
African national HIV treatment guidelines recommended ART for HIV
positives with WHO Stage 3 or 4 disease, CD4 count< 200 cells/μl, TB
disease or pregnancy with at CD4 counts< 350 cells/μl. [16] These
guidelines changed in March 2012 making patients who were HIV po-
sitive and had CD4 counts< 350 cells/μl, TB or were pregnant eligible
for ART regardless of CD4 count [17]. In 2016, CD4 criteria for ART
eligibility were removed, making all positive individuals eligible for
ART [18].
2.2. Randomization
Of 32 available clinics, 18 were purposively selected, i) ensuring
availability of TB diagnostic and treatment services, ii) at least 40 TB
patients registered at the clinic in the preceding year, iii) good geo-
graphic spread the sub-district (clinics not too close to one another) and
iv) absence of other competing research studies. The selected clinics
were stratiﬁed into high or low case-fatality clinics (i.e. TB CFR
rates> 3.5% OR ≤3.5% among smear-positive TB patients diagnosed
in 2010), and then randomly assigned within strata to either the in-
tervention or the control arm. Randomization was done by pulling
numbers out of bowls. This was done at a meeting with clinic managers
and sub-district health management staﬀ and facilitated by the trial
statistician.
2.3. Description of the intervention
The intervention was a set of activities to optimise the integration of
TB and HIV services beyond the level prevailing at the control clinics
and has been described previously. [14] Brieﬂy, the intervention were
any activities meant to address clinic level barriers to better delivery
and co-location of TB/HIV services at each intervention clinic. These
were tailored to the physical layout, human resources availability and
needs and priorities of the clinics with respect to TB/HIV integration. In
order to support the implementation of such activities, the trial in-
troduced two new staﬀ cadres – a TB/HIV integration oﬃcer (IO) and a
TB screening oﬃcer (SO). The IOs who were professional nurses with
prior TB/HIV experience. Following study speciﬁc training, the IOs
worked with clinic managers to identify gaps and barriers to eﬀective
TB and HIV service integration, to support the clinic with better de-
livery of TB and HIV collaborative services and to transition towards
the single provider model of TB/HIV integration as recommended by
the national TB/HIV integration guidelines [19]. At placement, both the
IOs and clinic staﬀ were made aware that the IOs were meant to be
catalysts for change, that the IOspresence in the clinics was limited to
the intervention period (1st September 2011–31st August 2013), and
that the clinics were expected to sustain any TB/HIV integration ac-
tivities initiated by the IOs beyond this intervention period.
The broad function of the SOs was to support the screening of HIV
positive individuals for TB, the demand for which was expected to in-
crease with better TB/HIV integration. The TB screening oﬃcers were
lay workers with previous experience of working in health care settings
and their placement was considered task shifting for TB screening- that
is use of lay workers in place of nurses to conduct TB screening. The SOs
were meant to work with the IOs, clinic staﬀ and managers to identify
bottlenecks to TB screening and determine where they would be best
located in the clinic in order to maximise the number of HIV positive
patients screened for TB. The location of the SOs in the clinics was also
allowed to vary depending on the physical layout and the ﬂow of pa-
tients in the clinics.Clinics were expected to identify a staﬀ member
who would continue with TB screening beyond the intervention period.
2.4. Description of the control clinics
In control clinics, TB and HIV services were provided as re-
commended by the South African National Department of Health
guidelines for TB/HIV integration. At randomization, these guidelines
recommended provision of all TB/HIV collaborative services including
on-site TB diagnostic services and ART initiations and encouraged the
physical integration of the services. [19] However implementation of
these guidelines in clinics was variable and sub-optimal with no clinic
providing the one-stop-shop model at baseline.
2.5. Baseline assessments and monitoring ﬁdelity to the intervention
At baseline, assessments of participating clinics were conducted to
establish clinic characteristics and the extent of co-location of TB and
HIV services. Fidelity to the intervention was assessed through bi-
monthly monitoring and supervision visits to intervention clinics by the
study coordinators and monthly group meetings for IOs and SOs. In
addition, the IOs and SOs also completed time sheets in order to
document how they spent their time in the clinics. At the end of the
intervention period, facility assessments were conducted in order to
measure the extent of TB/HIV integration at both intervention and
control clinics. During the assessments, quantitative data on clinic level
indicators of TB and HIV integration were collected from routine clinic
data for the preceding month (May 2013). In addition, assessments of
the location of key integrated TB/HIV services (i) TB screening for HIV
positive individuals, ii) HIV testing for individuals diagnosed with TB
patients and iii) ART treatment and monitoring for individuals diag-
nosed with both TB and HIV- were conducted. Fig. S1 shows the timing
of these activities during the trial.
2.6. Enrolment and follow up of evaluation cohorts
Research assistants placed at each clinic and with assistance from
clinic staﬀ, identiﬁed and enrolled a consecutive sample of clinic at-
tendees aged ≥18 years and i) newly diagnosed with TB, deﬁned as
T. Kufa et al. Contemporary Clinical Trials 72 (2018) 43–52
44
having initiated TB treatment in the 60 days preceding enrolment (TB
cohort) or ii) newly diagnosed with HIV, deﬁned as having tested HIV
positive in the 60 days preceding enrolment (HIV cohort) respectively.
Individuals who met inclusion criteria for both TB and HIV cohorts
were identiﬁed as the TBHIV cohort. At enrolment, baseline ques-
tionnaires were administered collecting information on participant
demographic and socioeconomic characteristics, TB screening, diag-
nosis and treatment, HIV testing, care and treatment and on factors
related to trial outcomes, as well as contact information for follow-up.
Enrolment of participants started at intervention clinics at least three
months after the start of the intervention, to allow time for the inter-
vention to have an eﬀect on clinic activity.
Participants were followed up through telephone interviews at six
monthly intervals for at least 12months and up to 18months for some
participants recruited earlier on. During the calls, data on clinic at-
tendance, TB and/or HIV care received were collected. Telephonic in-
terviews were considered necessary to measure outcomes of partici-
pants who transferred from or stopped attending care at the clinic of
enrolment.Research assistants also conducted medical record review
and abstractions. If participants could not be reached through the tel-
ephone, their next-of-kin were contacted and information on whether
participants had moved, been hospitalised or died obtained. For parti-
cipants who had a valid South African national identiﬁcation number,
the national vital statistics register was used to determine vital status
and date of death if the participant had died. Fig. S1 shows the timing of
participant enrolment in relation to the implementation of the inter-
vention.
2.7. Outcomes
The trial had three primary outcomes: i) the incidence of death or
hospitalisation in the HIV cohort; ii) the incidence of death or hospi-
talisation in the TB cohort; and iii) the 12-month retention in care in the
TBHIV cohort.Death was deﬁned as any death occurring during the
follow-up period as reported by any of next of kin OR detected through
the clinic records OR the vital statistics register. Hospitalisations were
either self-reported or reported by the next of kin during the follow-up
period (excluding those associated with pregnancy). Retention in care
among HIV positive individuals newly diagnosed with TB was deﬁned
as clinic attendance for routine HIV care with receipt of IPT, CPT, and
ART, CD4 or viral load testing which was self - reported or documented
on medical record review during the period 305 to 425 days from the
date of starting TB treatment. This corresponded to a 12month visit
post ART initiation with a 60 day window around the visit.
The study also had several secondary outcomes. These outcomes
were the comparison among intervention and control clinics oﬁ)
Proportion of the TB cohort whoknew their HIV status by the end of TB
treatment;ii) median CD4 count at enrolment in the HIV cohort;iii)
proportion of HIV cohort who started IPT within 12months of the HIV
test;iv) the proportion of the TB cohort who successfully completed TB
treatment during 12months of follow up;and v) the proportion of the
ART-eligible HIV cohortwho initiated ART by 10weeks after date of
CD4 count (based on the current guidelines). These secondary outcomes
were selected because they represented steps in the pathway from di-
agnosis of TB or HIV to primary outcomes and aimed to measure the
extent of delivery of integrated TB/HIV services. For both primary and
secondary outcomes individuals were considered to enter the cohort on
the date of the HIV test and date of starting TB treatment for the HIV
and TB cohorts respectively.
2.8. Sample size and statistical analysis
The sample size calculations took into account the clustered design
through the coeﬃcient of variation [20–22] and have been outlined
previously [14]. Brieﬂy, we assumed nine clinics per arm, a type I error
of 5%, a coeﬃcient of variation of 0.25 and 15months average follow-
up time for the hospitalisation/mortality outcome. We assumed a
sample size of 60 patients per clinic for the TB cohort and 165 patients
for the HIV cohort per clinic across the 18 clinics taking into account
refusals and loss to follow up [14].For the TB cohort, assuming an in-
cidence of hospitalisation or mortality of 20 per 100 person-years (py)
in the control clinics, the target sample size cited above gave 92%
power to assess a 50% reduction in either mortality or hospitalisation at
the intervention clinics [14]. For the HIV cohort, we assumed an in-
cidence of hospitalisation or mortality of 15 per 100 py in the control
clinics which gave 86% power to assess a 40% reduction in either
mortality or hospitalisation at the intervention clinics. For the retention
in care endpoint, we assumed that 70% of TB cohort would be HIV
positive and that 30% would not be retained in care over a 12-month
period in the control clinics. [14] This gave 90% power to assess a 50%
reduction in the proportion not retained over a 12-month period in the
intervention clinics.
For the primary outcome person time at risk was measured from
date of HIV test or starting TB treatment to the earlier of ﬁrst hospi-
talisation, death, or date last known to be alive, for the HIV and TB
cohorts, respectively. Date last known to be alive was deﬁned using
multiple data sources: date of most recent interview; date of most re-
cent routine clinic visit; date last seen alive as reported by the partici-
pant's next of kin (if participant was lost to follow-up); and the vital
statistics register (those with a South African identity number).
The analysis of the intervention eﬀect on primary and secondary
outcomes was based on comparisons of two arms (intervention vs
control) for in the three cohorts (TB, HIV and TBHIV cohorts).The
analyses generated cluster-level summaries and took into account the
stratiﬁed randomization. Brieﬂy, the logs of the cluster-level summaries
of the outcomes were used to calculate geometric means in each of the
two arms. An approximate standard error for the log (risk or rate) ratio
based on geometric means of cluster risks or rates were calculated by
two-way analysis of variance on randomization stratum, arm, and the
interaction between stratum and arm. The 95% conﬁdence interval (CI)
was calculated from this standard error, using a t-statistic with 14 de-
grees of freedom. An adjusted analysis, taking into account baseline
imbalances, was also conducted using a two-stage approach re-
commended for studies with a small number of clusters. [14, 21, 22]
Pre-speciﬁed subgroup analyses for sex, CD4 count strata (< 350 cells/
μl versus 350 or over cells/μl), social –economic status and enrolment
period (last year of enrolment versus earlier) were planned for all pri-
mary outcomes. Socioeconomic status was measured using the socio-
economic position index (deﬁned as the number of assets that the-
participant ownedoutof a list of 16 listed (working electric/gas stove,
working vacuum cleaner,working washing machine,working satellite
television,working digital videodisc[DVD] player, working motor/
car,working mail/ post box/bag,working mail delivery at home,-
working radio,working television [TV],working computer,working re-
frigerator,working landline telephone,working cell phone,working bi-
cycle,working motorcycle/ scooter). The scores were determined for
each participants and distribution of the index determined using prin-
cipal component analysis [23]. Participants who belonged to lower,
middle and upper thirds of this distribution were identiﬁed.This items
included in the index were adapted from a questionnaire used by Sta-
tistics South Africa household surveys [24].
2.9. Ethical considerations
Ethical clearance was obtained from the research ethics committees
of University of the Witwatersrand and the London School of Hygiene &
Tropical Medicine as well as from the Centres for Disease Control (CDC)
oﬃce of the Associate Director for Science.Permission to conduct the
study was also obtained from the Ekurhuleni District Department of
Family Health prior to randomization. The trial was registered on the
South African Register of Clinical Trials (registration number DOH-27-
1011-3846). Participants enrolled in the evaluation cohorts were
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requested to provide written informed consent before enrolment into
the study. The study was conducted according to ICH/GCP guidelines
and had oversight from a Data Monitoring Committee.
3. Findings
3.1. Description of clinics
At randomization, intervention clinics were comparable to control
clinics with respect to opening hours, adult head count per month and
the number of TB and HIV services provided (Supplementary Table
S1).During the enrolment and follow up periods, no clinics were
dropped from the trial (Fig. 1).
3.2. Fidelity to the intervention
The intervention was implemented over a 24-month period as
planned. IOs were present at all intervention clinics for 197 person-
months (91% of the intervention period), while SOs were present for
191 person-months (88% of the intervention period). From analyses of
timesheets and in-depth interviews, the main activities of the TB/HIV
integration oﬃcers were providing direct care to patients (mean
monthly proportion 39.6%), administration duties (mean 32.8%), re-
porting and recording TB and HIV activities (mean 10.6%), mentoring
counsellors and data clerks (mean 3.6%) (See Fig. S2), in contrast to the
leadership and coordination role envisaged at intervention design. The
main activities of the SOs were screening patients for TB, completing
registers and following up individuals with conﬁrmed TB who failed to
return to initiate TB treatment as intended at trial conception.
Intervention           Control 
18 clusters (clinics) 
Total participants 4003 
9 clusters allocated to intervention 
Screened for study eligibility 1999
Median participants per cluster; 242
(Range; 101-348) 
Non-eligible: 379 in 9 clusters  
(Range; 10-97) 
Declined enrolment: 53 in 8 clusters 
(range; 1-25) 
Enrolled:  
1567 participants (from 9 clusters)
Median participants per cluster; 183 
(Range; 85-248) 
Withdrawn: 27 in 8 clusters 
6 duplicates
3 found to be under-age  
4 missing consent forms
8 illiterate participants had no witnesses 
when giving consent
6 participants did not sign the consent 
form 
Analysed: 
1540 participants (from 9 clusters) 
Median participants per cluster; 180 
(Range; 81-247) 
1054 (68%) with valid SA ID numbers
1125 (73%) with 12-month follow-up 
9 clusters allocated to control 
Screened for study eligibility 2004
Median participants per cluster; 252
(Range; 109 -274) 
Non-eligible: 440 in 9 clusters  
(Range; 18-86) 
Declined enrolment: 67 in 9 clusters 
(range; 1-21) 
Enrolled:  
1497 participants (from 9 clusters)
Median participants per cluster; 193 
(Range; 77-224) 
Withdrawn: 13 in 7 clusters 
8 duplicates
2 missing consent forms
2 illiterate participants had no witnesses 
when giving consent
1 participant did not sign the consent 
form
Analysed: 
1484 participants (from 9 clusters) 
Median participants per cluster; 191
(Range; 76-224) 
975 (66%) with valid SA ID numbers 
1138 (72%) with 12-month follow-up 
Fig. 1. CONSORT diagram for the HIV cohort.
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3.3. Delivery of integrated TB/HIV service at intervention and control
clinics at the end of the intervention period
Overall, there was no diﬀerence in location and extent of delivery of
TB and HIV collaborative services based on facility assessments and
analysis of routine data at the end of the intervention period (see Tables
S2 and S3). However, at the end of the intervention period, there was a
higher proportion of newly diagnosed HIV positive clinic attendees
screened for TB (94.3% vs 39.1%) and a lower proportion of newly
diagnosed HIV positive clinic attendees initiated on IPT initiation
(29.1% vs 40.2%) at intervention clinics compared to control (see Table
S3).
3.4. Description of evaluation cohorts
Between January 2012 to July 2013, 4003 individuals were
screened for eligibility and 3393 participants were enrolled for follow
up until the end of July 2014 as planned. A total of 3024 participants
(1540 in intervention and 1484 in control arm) were eligible for in-
clusion in the HIV cohort (Fig. 1) and 731 (421 in intervention and 310
in control clinics) were eligible for inclusion in the TB cohort (Fig. 2).
There were 427 participants (173 control and 254 intervention clinics)
included in both cohorts and therefore made up the TBHIV cohort.
Figs. 1 and 2 show CONSORT diagrams for the TB and HIV cohorts.
Participants in both cohorts were comparable with respect to most
characteristics at enrolment, by arm (Tables 1 and 2). For the HIV co-
hort, however, participants in the intervention arm were more likely to
be South African born, to be unemployed, to have a lower asset count
and to be in the bottom third of the socio-economic position index, to
be on CPT at enrolment and less likely to be on ART at enrolment
compared to participants in the control arm. For the TB cohort, parti-
cipants in the intervention arm were also more likely to be South
African born and to be in the bottom third of the socio-economic po-
sition index compared to those in the control arm.
Intervention           Control 
18 clusters (clinics) 
Total participants 4003 
9 clusters allocated to intervention 
Screened for study eligibility 1999
Median participants per cluster; 242
(Range; 101-348) 
Non-eligible: 1519 in 9 clusters  
(Range; 89-275) 
Declined enrolment: 53 in 8 clusters 
(Range; 1-25) 
Enrolled:  
427 participants (from 9 clusters)
Median participants per cluster; 61 
(Range; 11-77) 
Withdrawn: 6 from 5 clusters 
2 found to be under-age 
1 missing consent form
2 illiterate participants had no witnesses 
when giving consent
1 participant did not sign the consent 
form
Analysed: 
421 participants (from 9 clusters) 
Median participants per cluster; 59
(Range; 11-77) 
312 (74%) with valid SA ID numbers
303 (72%) with 12-month follow-up 
9 clusters allocated to control 
Screened for study eligibility 2004
Median participants per cluster; 252
(Range; 109 -274) 
Non-eligible: 1625 in 9 clusters  
(Range; 101-222) 
Declined enrolment: 67 in 9 clusters 
(Range; 1-21) 
Enrolled:  
312 participants (from 9 clusters)
Median participants per cluster; 35 
(Range; 5-61) 
Withdrawn: 2 from 2 cluster 
2 duplicate enrolment  
Analysed: 
310 participants (from 9 clusters) 
Median participants per cluster; 35
(Range; 4-60) 
209 (67%) with valid SA ID numbers 
246 (79%) with 12-month follow-up 
Fig. 2. CONSORT diagram for the TB cohort.
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3.5. Eﬀect of the intervention on the co- primary outcomes of hospital
admissions and or mortality
The median follow-up for the HIV and TB cohorts was 12.3 and
12.2 months, respectively, and similar by arm.Among individuals in the
HIV cohort, the incidence of hospitalisation or death in 12months of
follow up was 12.5 per 100 person-years (py) (182/1459) and 10.4 per
100 py (147/1408) in the intervention and control clinics respectively,
giving an incidence rate ratio [IRR] of 1.17 (95% CI 0.92, 1.49), ad-
justing for randomization strata.After adjusting for age, sex, randomi-
zation strata and variables showing baseline imbalance the adjusted
IRR was 1.08 (95% CI 0.84–1.38) (Table 3 and Table S4 supplementary
appendix). In subgroup analyses, the eﬀects of the intervention were
similar by sex, socioeconomic position index (low versus high), and
year of enrolment and among those with CD4 counts< 350 cells/μl
(Table 4). In the TB cohort, the incidence of hospitalisation or death
was 17.1 per 100 py (67/392py) and 11.1 per 100py (32/289py) in the
intervention and control clinics respectively, giving an adjusted IRR
1.22 (95% CI 0.70–2.13) in a model adjusting for age, sex,
randomization strata and variables showing baseline imbalance (see
Table 3 and Tables S5 in the supplementary appendix). The sample was
too small to conduct subgroup analyses for this cohort.
3.6. Eﬀect of the intervention on the co-primary outcome of retention in
care
Of 338 individuals in the TB-HIV cohort, 213/338 (63.0%) were
retained in care by 12months in the intervention arm, compared to
143/256 (55.9%) in the control arm, giving an adjusted risk ratio (RR)
of 1.11 (95% CI 0.89–1.38) (Table 3), adjusting for randomization
strata. A fully-adjusted analysis gave similar results. The sample was too
small to conduct subgroup analyses (see Table 3 and Table S5 in the
supplementary appendix).
3.7. Eﬀect of the intervention on the secondary outcomes
Table 5 shows the eﬀect of the intervention on the secondary
Table 1
Characteristics of individuals who were newly diagnosed with HIV at enrolment
by arm (n=3024).
Characteristic Intervention
(1540)
Control (1484)
Age in years, median (IQR) 34.2 (28.5–40.2) 33.7(28.5–40)
Males, n (%) 608(39.5) 530(35.7)
Married or cohabiting, n (%)a 590(38.3) 678(45.7)
South African born, n (%)a 1285 (83.4) 1167 (78.6)
Completed grade 12 or higher, n (%)a 528(34.3) 606(40.8)
Employed, n (%)a 819(53.2) 876(59.0)
Asset count, median (IQR)a,b 6 (4–8) 7 (5–9)
In bottom one third of socio-economic
position index, n (%)c
575 (37.3) 410 (27.6)
Distance from clinic < 5 km, n (%) 1154 (74.9) 1111 (74.9)
Lived alone, n (%) 273(17.8) 303(20.4)
Length of time in town (years),median
(IQR), n
7 (1–14) 5(1−13)
Ever smoked, n (%) 375 (24.4) 361 (24.3)
Currently drink alcohol, n (%) 345 (22.4) 345 (23.2)
Hospitalized in the last 12months, n (%) 264 (17.1) 233 (15.7)
Know someone who was ill or died from
HIV, n (%)
814 (52.9) 870 (58.6)
Believes that traditional healers can treat
HIV, n (%)
99 (6.5) 134 (9.0)
Ever treated for TB 120 (7.8) 100 (6.7)
Newly diagnosedwith TB 254 (16.5) 173 (11.7)
Duration since HIV test (median, IQR) 12 (7–21) 11 (7–20)
On CPT at enrolment, n (%)a,d 602(39.1) 472(31.8)
IPT use at or prior to enrolment, n (%)a,d 168(10.9) 208(14.5)
Attending usual clinic for HIV care, n (%) 1461 (94.9) 1418 (95.6)
On ART at enrolment, n (%)a,d 331 (21.5) 397(26.8)
Pregnanta,e 157 (16.9) 236 (24.8)
IQR - interquartile range.
a Variables for which there appeared to be some imbalance between arms.
b The number of assets the participant owned out 16 assets listed (working
electric/gas stove, working vacuum cleaner, working washing machine,
working satellite television, working digital video disc (DVD) player, working
motor/car, working mail/ post box/bag, working mail delivery at home,
working radio, working TV, working computer, working refrigerator, working
landline telephone, working cellphone, working bicycle, Working motorcycle/
scooter).
c Based on a socio-economic position index with the following elements
(assets, water source, type of toilet, type of ﬂoors and walls at participants
dwelling). Variables to include in the SEP index determined through principal
component analysis.
d Started Isoniazid preventive therapy (IPT), Cotrimoxazole preventive
therapy (CPT) or antiretroviral therapy (ART) prior to or on the day of enrol-
ment.
e Out of 931 females at intervention clinics and 953 females at control
clinics.
Table 2
Characteristics of individuals who were newly diagnosed with TB at enrolment
by arm (N=731).
Characteristic Intervention(421) Control (310)
Age in years, median (IQR) 36.6 (29.3–42.7) 35.9(29.6–42.7)
Males, n (%) 225 (53.4) 173(55.8)
Married or cohabiting, n (%) 151(35.9) 125(40.3)
South African born, n (%)a 379(90) 249(80.3)
Completed grade 12 or higher, n (%)a 152(36.1) 143(46.1)
Employed, n (%) 226(53.7) 179(57.7)
Total asset count, median (IQR),b 7 (4–8) 7 (5–9)
In bottom one third of socio-economic
position index, n (%)c
164 (39.0) 77 (24.8)
Distance from clinic < 5 km, n (%) 324 (77) 234(75.5)
Worked in the mines, n (%)a 31(7.4) 11(3.5)
Lived alone, n (%) 71(16.7) 50(16.1)
Length of timein town, median (IQR) 7(1–15) 6 (2–14.5)
Ever smoked, n (%) 133(31.6) 93 (30)
Currently drink alcohol, n (%) 74 (17.6) 71 (22.9)
Previous TB treatment (n, %) 65(15.4) 40(12.9)
Hospitalised in the last 12months, n (%) 115 (27.3) 82 (26.5)
Know someone who was ill or died from
HIV, n (%)a
185 (43.9) 187(60.3)
Believes that traditional healers can treat
HIV, n (%)
23 (5.5) 14(4.5)
Documented HIV test at enrolment, n (%) 396 (94.1) 288(92.9)
HIV positive at enrolment, n (%) 329(78.1) 254 (81.9)
Duration since HIV test (median, IQR) 20 (7–44) 21 (8–62)
Newly diagnosed HIV positive, n (%) 245 (58.2) 172 (55.5)
On CPT at enrolment, n (%)a,d,e 186(56.5) 106(41.7)
On ART at enrolment, n (%)d,e 91 (27.7) 79(31.1)
Pregnant, n (%)f 8 (4.1) 5 (3.7)
IQR- interquartile range.
a Variables for which there appeared to be imbalance between arms.
b The number of assets the participant owned out the 16 listed (working
electric/gas stove, working vacuum cleaner, working washing machine,
working satellite television, working digital video disc (DVD) player, working
motor/ car, working mail/ post box/bag, working mail delivery at home,
working radio, working television (TV), working computer, working re-
frigerator, working landline telephone, working cell phone, working bicycle,
Working motorcycle/ scooter).
c Based on a socio-economic position index with the following elements
based on a socio-economic position index with the following elements (assets,
water source, type of toilet, type of ﬂoors and walls at participants dwelling).
Variables to include in the SEP index determined through principal component
analysis.
d Denominator is HIV positive TB patients (329 in the intervention arm and
254 in the control arm).
e started Cotrimoxazole preventive therapy (CPT) or antiretroviral therapy
(ART) prior to or on the day of enrolment.
f Out of 196 females at intervention clinics and 136 females at control clinics.
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outcomes. Because of high coverage of HIV testing at enrolment in both
arms (94.1% in the intervention arm vs. 92.9% in the control clinics),
the outcome of proportion of the TB cohort who knew their HIV status
by the end of TB treatment was not determined. There was no diﬀer-
ence in the mean CD4 counts at enrolment among those in the HIV
cohort between the arms (232 cells/μl [standard deviation (SD)
181 cells/μl] in the intervention arm vs 246 cells/μl [SD 197 cells/μl in
the control arms], adjusted mean diﬀerence in square root of CD4 count
0.14 (95% CI -0.64, 0.92)]. There wereno signiﬁcant diﬀerencesin the i)
proportions of ART eligible individuals in the HIV cohort who initiated
ART by 10weeks after CD4 count testing- a median 10 days after HIV
testing (67% vs 70.4%, RR 0.90 [95% CI 0.75–1.10]), ii) ART eligible
individuals in the TB cohort who started ART by 10weeks of HIV
testing (39.3% vs 38.8%, RR 1.05 [95% CI0.67–1.63]), iii) individuals
in the HIV cohort who started IPT by the end of 12months (39.8% vs
42.6, RR 0.94 [95% CI 0.64–1.33]) and iv) individuals newly diagnosed
with TB who successfully completed TB treatment during 12months of
follow up (76.7% vs 78.4%, RR 0.94 [95% CI 0.83–1.06]), after ad-
justing for randomization strata (Tables 5 and S7–S11 in the supple-
mentary appendix).
4. Discussion
This cluster-randomised trial evaluated the eﬀect of an intervention
to optimise the delivery of integrated TB and HIV care on patient re-
levant outcomes. The intervention as implemented in the trial did not
have an eﬀect on morbidity, mortality and retention in care among
individuals newly diagnosed with TB or HIV. This was most likely be-
cause the intervention did not succeed in improving coordinated de-
livery and co-location of TB/HIV services beyond the levels at the
control clinics.
This trial intervention was intended to address lack of coordination
as a barrier to TB/HIV integration while taking into account variability
in other TB/HIV integration-related challenges and clinic-level re-
sponses to them. The IO and SO were meant to be catalysts for im-
proved TB/HIV integration while demonstrating that assigning speciﬁc
health cadres to focus on TB/HIV integration alone could improve de-
livery of the services. Implementation of the intervention was expected
to result in increased proportions of HIV positive individuals tested
earlier in the course of the infection, screened for TB and started on IPT
as well as increased proportions of individuals diagnosed with TB who
are tested for HIV, started on CPT or ART thereby reducing morbidity
and mortality.
Although the implementation of this trial intervention was sub-op-
timal and failed to improve integration, observational studies con-
ducted elsewhere have not consistently demonstrated reductions in
mortality with better integration. Most studies that have assessed the
eﬀect of improved TB/HIV integration have evaluated the eﬀect of
improved co-location of TB and HIV services, comparing vertical ser-
vices or with the same services before and after implementation. Some
of these studies reported more rapid ART start and higher median CD4
counts at ART initiations among HIV positive individuals diagnosed
with TB [7–10] while others reported no eﬀect on ART uptake [5,
24–26]. In addition, with respect to TB treatment outcomes among HIV
positive individuals, some studies found reduced mortality and better
retention [9, 10, 27, 28], where others did not [10, 25, 26, 29–31].
Complex health systems interventions to improve TB/HIV integration
have also been evaluated in trials. The PALSA PLUS trial evaluated the
eﬀect of a non-didactic, outreach- and case-based training on HIV,
sexually transmitted infections, and TB for nurses. This intervention
increased TB case detection and CPT uptake among eligible individuals
newly diagnosed with HIV but did not reduce mortality [32]. The
STRETCH trial added task shifting of ART initiation, further ART
training, introduction of ART initiation algorithms and management
support to the PALSA PLUS training; this did not reduce mortality
among patients eligible but not started ART at enrolment or improveTa
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12month viral suppression rates among those on ART for at least six
months at enrolment [32].
Our study had a number of important strengths. Firstly, we used a
clustered randomised study design with a large sample size and a
reasonable number of clinics. Secondly, because we assumed that the
delivery of TB/HIV services was already integrated, to a variable de-
gree, in most clinics, we designed an intervention, which was pragmatic
and allowed the activities for optimising integrated TB/HIV care to vary
Table 4
Eﬀect of the intervention among subgroups of sex, socio-economic position (SEP) index, enrolment period and baseline CD4 on incidence of hospitalizations and
mortality among individuals newly diagnosed with HIV.
Intervention arm Control arm Adjusted rate
ratioa
p-Valuea Adjusted rate
ratiob
p-Valueb
N (Hospitalisation or deaths/person-years of
follow up) Incidence per 100 person-years
N (Hospitalisation or deaths/person-years of
follow up) Incidence per 100 person-years
Sex:
Male 608 (82/571) 14.4 530 (56/498)11.2 1.21 (0.81,
1.79)
0.33 1.1 (0.76,
1.71)
0.51
Female 931 (100/887) 11.3 953 (91/909)10.0 1.15 (0.83,
1.58)
0.37 1.05 (0.76,
1.46)
0.74
SEP index:
Low 982 (119/926) 12.8 646 (64/620) 10.3 1.11 (0.69,
1.79)
0.64 1.02 (0.65,
1.61)
0.91
High 558 (63/533) 11.8 838 (83/788) 10.5 1.03 (0.61,
1.73)
0.91 0.94 (0.53,
1.66)
0.82
Enrolment
periodc
Earlyd 358 (48/365) 13.2 281 (41/290) 14.1 N/A N/A
Late 1182 (134/1095) 12.2 1203 (106/1118) 9.5 1.37 (0.92,
2.03)
0.11 1.26 (0.84,
1.90)
0.24
Baseline CD4e
<350 1100 (147/1037) 14.2 1036 (110/988) 11.1 1.25 (0.97,
1.61)
0.09 1.14 (0.88,
1.48)
0.31
≥350f 251 (9/253) 3.6 273 (20/263) 7.6 N/A N/A
N/A not applicable – analysis not conducted as too few outcomes at the clinic level.
a Adjusted for randomization strata.
b Adjusted for randomization strata, sex, age group, country of birth, education level, marital status, employment status, Socioeconomic position index, on
antiretroviral therapy (ART) at enrolment, Cotrimoxazole preventive therapy (CPT) at enrolment and in TB cohort.
c Early enrolment period deﬁned as being enrolled before 1 September 2012 (≥ 12months of intervention).
d Four clusters in the control arm and three clusters in the control arm have< 10 participants in the early enrolment period. Analysis is not possible for this
stratum.
e CD4 count measured within 90 days of enrolment. 12% (364/3014) of participants have a missing CD4 count (175/1484 and 189/1540) in the control and
interventions arms, respectively).
f Two clusters in the intervention and control arms (4/18) have zero outcomes. Analysis was not undertaken for this stratum.
Table 5
Eﬀect of the intervention on secondary outcomes of CD4 counts at enrolment, time to starting ART among ART eligible individuals, proportion started on Isoniazid
preventive therapy (IPT) by the end of 12months follow up and proportion who successfully completed TB treatment during 12months of follow up.
Intervention arm
(Overall mean, N)
Control arm
(Overall mean, N)
Adjusted mean diﬀerence
(control-intervention)a
p-valueb Adjusted mean diﬀerence
(intervention-control)c
p-value
Square root of CD4 counts at enrolment
among participants newly diagnosed
with HIVa
14.0, 1315 14.4, 1309 −0.28 (−1.14, 0.58)a 0.50 0.14 (−0.64, 0.92) 0.72
n/N, (%) n/N, (%) Adjusted RR p-value Adjusted RR p-value
Proportion of individuals newly diagnosed with HIV,ART eligiblewho initiated ART
by the end of 10 weeks after CD4 testing
597/891 (67) 626/889
(70.4)
0.90 (0.75–1.10) 0.30 0.91 (0.71–1.10)d 0.30
Proportion ofHIV positive individuals newly diagnosed with TB who started ART by
10weeks after HIV testing
88/224 (39.3) 62/160 (38.8) 1.05(0.67–1.63) 0.83 0.99 (0.64–1.54)d 0.93
Proportion of individuals newly diagnosed with HIV who started IPT by 12months
after HIV testing
503/1264
(39.8)
552/1295
(42.6)
0.94(0.64–1.33) 0.71 0.96 (0.68–1.35)e 0.79
Proportion of individuals newly diagnosed with TBwho successfully completed TB
treatment during 12months of follow up
323/421
(76.7)
243/310
(78.4)
0.94 (0.83–1.06) 0.28 0.93(0.82–1.05)f 0.23
a Untransformed: for the intervention arm overall arithmetic mean is 230.8 (and arithmetic mean of cluster means is 231.5); for the control arm overall arithmetic
mean is 245.7 (and arithmetic mean of cluster means is 242.0).
b Adjusted for randomization strata.
c Adjusted for randomization strata, sex, age group, country of birth, education level, marital status, employment status, Socioeconomic position (SEP) level, on
antiretroviral therapy (ART)at enrolment, Cotrimoxazole preventive therapy(CPT)at enrolment and in TB cohort.
d Adjusted for randomization strata, sex, age group, country of birth, education level, marital status, employment status, SEP level, CPT at enrolment.
e Adjusted for randomization strata, sex, age group, country of birth, education level, marital status, employment status, SEP level, on ART at enrolment, CPT at
enrolment.
f Adjusted for randomization strata, sex, age group, country of birth, education level, marital status, SEP level, CPT at enrolment and being in the HIV cohort.
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slightly depending on clinic needs. Thirdly, the trial enrolled in-
dividuals newly diagnosed with TB, as well as individuals newly diag-
nosed with HIV, and would have been able to evaluate the potential
impact of the intervention on outcomes speciﬁc to individuals in both
groups. Our trial showed that individuals newly diagnosed with HIV
alone did not have worse outcomes where TB/HIV integration was
being actively promoted [12].
A number of factors may explain our intervention's apparent lack of
eﬀect on both improved TB/HIV integration and patient relevant out-
comes. These factors are related to: i) limited implementation of the
intervention as intended, ii) diﬀerences between arms and, iii) lack of
statistical power.
From the facility assessments at the end of the intervention period
and process measures (secondary outcomes), the extent to which in-
tegrated care was delivered at intervention clinics was not signiﬁcantly
diﬀerent from that at the control clinics. More robust measurements of
TB/HIV integrated service delivery levels were not possible prior to,
during or at the end of the trials as there were no validated tools or
systems in use.The intervention may also have failed to deliver the
expected result because the integration oﬃcers did not play the co-
ordination and mentorship role envisaged but instead spent signiﬁcant
amounts of time providing direct care to patients. The integration of-
ﬁcers may have focussed on this aspect in order to better ‘ﬁt in’ to the
clinic working routines.As outsiders, the IO may have faced some re-
sistance to changing practice given the prevalent organisational culture
within clinics, and hence spent more time on being accepted by con-
tributing to clinic work rather than pushing for change. This can also be
partly explained in the context of staﬀ shortages as well as lack of staﬀ
training and motivation in both intervention and control clinics that
limited the extent to which integrated care at intervention clinics could
be improved [33, 34].
As standard of care evolved over time, control clinics may have
advanced in the delivery of integrated TB/HIV services more than ex-
pected, which may have diluted the eﬀect of the intervention.The IOs
and SOs presence in the clinics may also have improved record keeping
in the intervention clinics leading to better ascertainment of hospitali-
zations and other outcomes, although this was unlikely to be a major
contributory factor as there were statistically diﬀerences in follow up
by arm. In addition, participants enrolled into the evaluation cohorts at
control clinics were more educated, more likely to be employed, less
likely to be in the lower third of the socio-economic position index and
more likely to have been on ART at enrolment compared to those at the
intervention clinics. On the other hand, intervention clinics may have
been able to improve linkage into care for the very ill as indicated by
the higher proportion of HIV positive individuals newly diagnosed with
TB in that arm. The adjustments for cluster level imbalance at analysis
are likely to have minimised the eﬀects of these imbalances.
The trial was also unable to meet the desired sample size and
median duration of follow up (expected 15months follow up) for both
cohorts and therefore may not have had adequate power to detect the
large diﬀerences (40% reduction) between the arms assumed at sample
size calculations. However, the small eﬀect sizes for all the primary
outcomes and their consistency across a range of sensitivity analyses
suggest that that no important diﬀerences between the arms would
have been observed had the trial been adequately powered.
Despite these limitations, this trial contributed some valuable les-
sons about the delivery of integrated TB/HIV services and patient
outcomes. Firstly, that task shifting for TB screening is feasible at pri-
mary care facilities. Secondly, there is a need to strengthen HIV testing
and linkage into HIV care at higher CD4 counts. This is because re-
gardless of arm, there were low CD4 counts at HIV testing and linkage
into care; 48.5% of individuals in the HIV cohort had CD4 count<
200 cells/ml and 69% had initiated ART 10weeks after CD4 count
testing) despite a national HIV testing campaigns and increased
thresholds for ART initiation both introduced during the intervention
period. In September 2016, the South African government introduced
the test and treat strategy which saw all HIV positive individuals being
eligible for ART regardless of CD4 count. [16] The impact of this
strategy will be limited by how early HIV positive individuals are
identiﬁed and initiated on ART.Thirdly, there is a need to scale up in-
terventions that promote the scale-up of IPT in order to prevent TB
among HIV positive individuals. In the trial, there were low levels of
IPT initiation in 12months (42% of eligible) following HIV testing.
In conclusion, the trial intervention did not show an eﬀect on pa-
tient relevant outcomes, because it had an insuﬃcient eﬀect on in-
tegration of care.Alternative strategies are needed to achieve closer
integration of TB and HIV care, taking resource constraints and existing
organisational culture into account, along with evaluation of the eﬀect
on patient-relevant outcomes.
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